Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
17 Julio 2023 - 7:30AM
LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”)
(Nasdaq: LIXT and LIXTW) today announced that a recently posted
article in BioRxiv
(https://www.biorxiv.org/content/10.1101/2023.07.12.548685v1),
based on the results of a collaboration between the Company and the
Netherlands Cancer Institute, shows that inhibition of PP2A in
colon cancer cells, using LIXTE’s lead clinical compound LB-100,
leads to major changes in the way cancer cells process their mRNAs.
Based on this finding, cancer cells are
predicted to produce a significant number of aberrant proteins that
can be recognized by the immune system. This newly discovered
mechanism, by which LB-100 turns immunologically “cold” tumors
“hot,” adds to several additional mechanisms that have recently
been described through which LB-100 sensitizes cancer cells to
immune checkpoint blockade.
John S. Kovach, M.D., CEO and Founder of LIXTE,
said, “The case for combining LB-100 with immunotherapy is based on
extensive pre-clinical data. The new findings provide a clear
mechanistic underpinning for why this synergy is being seen. This
data further supports our focus on developing LB-100 in combination
with checkpoint blockade antibodies and strengthens our expectation
that our current and upcoming clinical trials combining LB-100 with
immune checkpoint blockade will be effective in treating
cancer.”
The Company said the new research also shows
that disruption of proper mRNA maturation induced by LB-100 leads
to a reduced ability of the cancer cells to deal with DNA damage.
This finding concurs with multiple pre-clinical studies
demonstrating synergy between LB-100 and radiotherapy or different
chemotherapies in various cancer models.
The July 13, 2023 BioRxiv article, titled “PP2A
Inhibition Instructs Spliceosome Phosphorylation to Create Splicing
Vulnerability in Colon Adenocarcinoma,” was authored by Dias et.
al. from the Netherlands Cancer Institute, in a collaboration that
LIXTE initiated in 2021 with a team of scientists headed by René
Bernards, a Professor of Molecular Carcinogenesis at the
Netherlands Cancer Institute and a member of the LIXTE Board of
Directors.
Prof. Bernards said, “There is strong scientific
evidence to support the notion that incorrectly spliced mRNAs, as
we see in cells treated with LB-100, are a rich source of
neo-antigens that can render cancer cells much more sensitive to
immunotherapies. Other companies are developing drugs that target
mRNA splicing for this reason, but we are not aware of any that
have reached the clinic. That LB-100 has such an unexpectedly
strong effect on mRNA splicing is a nice surprise that further
supports its use in combination with immunotherapy.”
About LIXTE Biotechnology Holdings,
Inc.
LIXTE Biotechnology Holdings, Inc. is a
clinical-stage pharmaceutical company focused on new targets for
cancer drug development and developing and commercializing cancer
therapies. LIXTE has achieved a breakthrough demonstrating that its
first-in-class lead clinical PP2A inhibitor, LB-100, is
well-tolerated in cancer patients at doses associated with
anti-cancer activity. Based on extensive published pre-clinical
data (see www.lixte.com), LB-100 has the potential to
significantly improve outcomes for patients undergoing various
chemotherapies or immunotherapies. LIXTE's new approach has no
known competitors and is covered by a comprehensive patent
portfolio. Initial proof-of-concept clinical trials are in
progress.
Forward-Looking Statements
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future activities, including the continuing development of
proprietary compounds, the planning, funding, coordination and
potential results of clinical trials, and the patent and legal
costs to protect and maintain the Company's intellectual property
worldwide, are all forward-looking statements. These statements are
generally accompanied by words such as "intend," anticipate,"
"believe," "estimate," "potential(ly)," "continue," "forecast,"
"predict," "plan," "may," "will," "could," "would," "should,"
"expect" or the negative of such terms or other comparable
terminology. The Company believes that the assumptions and
expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission
at https://www.sec.gov.
For more information about
LIXTE, Contact:
info@lixte.comGeneral Phone: (631) 830-7092Investor Phone: (888)
289-5533
or
PondelWilkinson Inc. Investor
Relationspwinvestor@pondel.comRoger Pondel: (310) 279-5965Laurie
Berman: (310) 279-5962
Lixte Biotechnology (NASDAQ:LIXTW)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Lixte Biotechnology (NASDAQ:LIXTW)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024